Telomir Pharmaceuticals Inc. (NASDAQ:TELO) shares surged 27.5% in premarket trading on Tuesday after the preclinical-stage biotechnology firm announced new data showing that its experimental therapy Telomir-1 successfully reactivated key tumor suppressor genes in prostate cancer models.
According to the company, Telomir-1 reactivated two critical tumor suppressor genes — MASPIN (referred to as a “tumor suppressor shield”) and RASSF1A (described as the “guardian gene”) — through DNA methylation reset in preclinical prostate cancer studies. Both genes are known to play essential roles in inhibiting tumor invasion and metastasis.
The findings revealed that MASPIN, a natural defense protein that blocks tumor spread and enhances treatment sensitivity, had been silenced by DNA hypermethylation in an aggressive prostate cancer model. Telomir-1 reversed this effect, restoring MASPIN activity. Similarly, the therapy reduced RASSF1A methylation in a dose-dependent manner, with stronger results observed when combined with chemotherapy.
“The potential reactivation of MASPIN and RASSF1A by inhibition of hypermethylation is highly significant because these genes play a central role in blocking tumor invasion, uncontrolled growth, and metastasis,” said Dr. Itzchak Angel, Chief Scientific Advisor at Telomir.
These results expand on earlier preclinical findings showing that Telomir-1 can reactivate other tumor suppressors, inhibit histone demethylases, restore mitochondrial function, and reduce tumor volume by about 50% in aggressive prostate cancer models.
Telomir said it is continuing to advance Telomir-1 through preclinical and IND-enabling studies, with further testing underway in prostate cancer and other high-risk tumor types.
Telomir Pharmaceuticals stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.